Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 331 AL 345

Alzheimer disease neuropathology in a patient previously treated with aducanumab

Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C, Castrillo-Viguera C, Sandrock A, Budd Haeberlein S, van Dyck CH, Huttner A.

Acta Neuropathol. 2022 Jul;144(1):143-153. doi: 10.1007/s00401-022-02433-4. Epub 2022 May 17.

The Current Landscape of Prevention Trials in Dementia

Lee J, Howard RS, Schneider LS.

Neurotherapeutics. 2022 Jan;19(1):228-247. doi: 10.1007/s13311-022-01236-5. Epub 2022 May 19.

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD.

J Nucl Med. 2022 Jun;63(Suppl 1):13S-19S. doi: 10.2967/jnumed.121.263195.

Curcumin Scaffold as a Multifunctional Tool for Alzheimer's Disease Research

Yang H, Zeng F, Luo Y, Zheng C, Ran C, Yang J.

Molecules. 2022 Jun 17;27(12):3879. doi: 10.3390/molecules27123879.

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease

Cohen S, Cummings J, Knox S, Potashman M, Harrison J.

J Prev Alzheimers Dis. 2022;9(3):507-522. doi: 10.14283/jpad.2022.41.

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study

Cuberas-Borrós G, Roca I, Castell-Conesa J, Núñez L, Boada M, López OL, Grifols C, Barceló M, Pareto D, Páez A.

Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4589-4600. doi: 10.1007/s00259-022-05915-5. Epub 2022 Jul 22.

Intermittent theta burst stimulation for the treatment of autonomic dysfunction and depressive symptoms in dementia with Lewy bodies

Huang CC, Liang CS, Chu HT, Chang HA, Yeh TC.

Asian J Psychiatr. 2022 Sep;75:103212. doi: 10.1016/j.ajp.2022.103212. Epub 2022 Jul 16.

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Hoang K, Watt H, Golemme M, Perry RJ, Ritchie C, Wilson D, Pickett J, Fox C, Howard R, Malhotra PA.

Trials. 2022 Aug 1;23(1):623. doi: 10.1186/s13063-022-06190-3.

A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia

Yang Q, Liu J, Huang KL, Wang GY, Wang MY, Tan AH, Ran SM.

Medicine (Baltimore). 2022 Aug 5;101(31):e29307. doi: 10.1097/MD.0000000000029307.

Effects of magnesium valproate adjuvant therapy on patients with dementia: A systematic review and meta-analysis

Zhang C, Sun L, Sun H.

Medicine (Baltimore). 2022 Aug 5;101(31):e29642. doi: 10.1097/MD.0000000000029642.

New Possibilities in the Therapeutic Approach to Alzheimer's Disease

Doroszkiewicz J, Mroczko B.

Int J Mol Sci. 2022 Aug 10;23(16):8902. doi: 10.3390/ijms23168902.

Opportunities and challenges in delivering biologics for Alzheimer's disease by low-intensity ultrasound

Chen L, Cruz E, Oikari LE, Padmanabhan P, Song J, Götz J.

Adv Drug Deliv Rev. 2022 Oct;189:114517. doi: 10.1016/j.addr.2022.114517. Epub 2022 Aug 25.

Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis

Jeong SY, Suh CH, Shim WH, Lim JS, Lee JH, Kim SJ.

Neurology. 2022 Nov 8;99(19):e2092-e2101. doi: 10.1212/WNL.0000000000201019. Epub 2022 Aug 29.

Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

Wei S, Dang L, Gao F, Wang J, Wang J, Qu Q.

J Alzheimers Dis. 2022;90(1):349-362. doi: 10.3233/JAD-220240.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias